Literature DB >> 1855349

The influence of dosage time of midazolam on its pharmacokinetics and effects in humans.

R Koopmans1, J Dingemanse, M Danhof, G P Horsten, C J van Boxtel.   

Abstract

The influence of dosage time of midazolam on its pharmacokinetics and effects on the central nervous system were investigated in six healthy volunteers, with pharmacokinetic-pharmacodynamic modeling. Each volunteer received single oral doses of 15 mg midazolam on four separate occasions: 8 AM, 2 PM, 8 PM, and 2 AM. An almost significant circadian variation was found in elimination half-life, shortest at 2 PM (1.26 +/- 0.47 hours, mean +/- SD) and longest at 2 AM (1.57 +/- 0.44 hours) (p = 0.05). Drug effects measured were alpha activity of the electroencepalograph and P100 latency of the visual-evoked response. The maximum drug effect (Emax) model described the concentration-effect relationship, extended with either a threshold drug concentration or a sigmoidicity parameter. A significant circadian variation was found in baseline alpha activity: highest at 8 AM (109% +/- 19% of the 24-hour mean) and lowest at 2 AM (80% +/- 12%). For alpha activity the drug concentration at half-maximum effect of both threshold Emax model and sigmoid Emax model showed lower values at 8 AM and 2 AM and higher values at 2 PM and 8 PM. However, these differences were either not significant (p = 0.10, threshold model) or on the verge of statistical significance (p = 0.05, sigmoid model). No circadian variation was found in the parameters describing the effect on the visual-evoked response. We conclude that the sensitivity of the central nervous system to midazolam, as reflected in alpha activity, possibly shows a circadian variation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855349     DOI: 10.1038/clpt.1991.99

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Association between use of benzodiazepines and risk of fractures: a meta-analysis.

Authors:  D Xing; X L Ma; J X Ma; J Wang; Y Yang; Y Chen
Journal:  Osteoporos Int       Date:  2013-09-07       Impact factor: 4.507

Review 2.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 3.  Benzodiazepines and risk of hip fractures in older people: a review of the evidence.

Authors:  Robert G Cumming; David G Le Couteur
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers.

Authors:  A van Rongen; L Kervezee; Mje Brill; H van Meir; J den Hartigh; H-J Guchelaar; J H Meijer; J Burggraaf; F van Oosterhout
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-07-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.